Clinical Research Directory
Browse clinical research sites, groups, and studies.
Using ctDNA Methylation to Monitor Metastatic Colorectal Cancer Treatment (PROMET)
Sponsor: Fudan University
Summary
Multi-center observational clinical study to evaluate the application value of ctDNA methylation monitoring in efficacy assessment and relapse prediction in patients diagnosed with recurrence or metastatic colorectal cancer receiving radiotherapy plus SOC with or without PD-1.
Official title: ctDNA Methylation for Efficacy Assessment and Prognostic Prediction in Advanced Colorectal Cancer Treated With Radiotherapy Combined With or Without PD-1 Inhibitor: A Prospective Cohort Study (PROMET)
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
OBSERVATIONAL
Enrollment
497
Start Date
2025-10-10
Completion Date
2030-10-10
Last Updated
2025-12-16
Healthy Volunteers
No
Interventions
Plasma ctDNA methylation profiling
Plasma ctDNA methylation profiling was performed using an optimized single-tube multiplex mqMSP assay
Locations (1)
Fudan University Shanghai Cancer Center
Shanghai, China